AHA Conference 2024 - 128-week results of VALOR-HCM investigating mavacamten treatment for patients with hypertrophic cardiomyopathy (HCM) referred for septal reduction therapy (SRT) procedures.

Dr Milind Desai (Cleveland Clinic, Ohio, US) joins us onsite at AHA Conference to discuss the findings from VALOR-HCM (NCT04349072).

VALOR-HCM is a randomized, double-blind, placebo-controlled, phase 3 trial in the United States investigating the use of mavacamten in patients with symptomatic obstructive hypertrophic cardiomyopathy who are eligible and willing to undergo SRT procedures. 112 patients were enrolled in the trial and were followed-up at week 16 and from baseline to week 16. The primary outcome measures were a composite of the decision to proceed with SRT and to remain guideline eligible for SRT.

Interview Questions:
1.    What are the current unmet needs in hypertrophic cardiomyopathy management?
2.    Could you tell us about the mechanism of action behind mavacamten?
3.    What was the study design and patient population?
4.    What were the key findings?
5.    What are the take-home messages for practice?
6.    What further research is needed in this area?

Recorded on-site at AHA Conference in Chicago, 2024.

Editors: Yazmin Sadik, Jordan Rance
Videographers: Mike Knight, Dan Brent, Oliver Miles, Tom Green, David Ben-Harosh.

Support: This is an independent interview produced by Radcliffe Cardiology.